With the recent launch of over 1,600 new products in the areas of neuroscience, cancer biology, immunology, inflammation and arthritis, diabetes and vision research, ABR-Affinity BioReagents’s portfolio of high quality antibodies is said to grow in breadth and depth of research reagents available worldwide.
Ken Wilczek, president of ABR-Affinity BioReagents, said: “These types of international distribution arrangements allow us the ability and flexibility to offer our quality guaranteed experimental research tools to foreign-based scientists who are active in the worldwide effort to combat disease and enhance the quality of life for everyone.”